Related Pages Lung Cancer Home Page 1 NCI's gateway for information about lung cancer. Search for Clinical Trials 2 NCI's PDQ® registry of cancer clinical trials. Lung Cancer Trial Results 26.  Presence of Gene Mutation Tightly Linked to Drug Effectiveness in Lung Cancer 3 (Posted: 04/29/2004) - Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa) will show a beneficial response. 27.  Post-Surgery Chemotherapy Boosts Survival for NSCLC Patients 4 (Posted: 06/02/2003, Updated: 02/10/2004) - A large international study has shown that patients with the most common form of lung cancer -- non-small cell lung cancer, or NSCLC – may live longer if they are treated with chemotherapy after surgery. These results may justify post-operative chemotherapy for NSCLC patients in otherwise good health. 28.  Pemetrexed (Alimta®) Is a Less-Toxic Alternative for Recurrent Lung Cancer 5 (Posted: 06/12/2003, Reviewed: 11/16/2005) - The experimental drug pemetrexed (Alimta®) was as effective as the current standard treatment for recurrent non-small cell lung cancer (NSCLC) and caused fewer side effects, according to data presented at American Society of Clinical Oncology (ASCO) annual meeting on June 2, 2003. 29.  Three-Pronged Approach an Added Treatment Option for Metastatic NSCLC 6 (Posted: 06/02/2003, Reviewed: 11/16/2005) - Patients with non-small-cell lung cancer (NSCLC) that has spread to surrounding lymph nodes who were treated with a three-pronged approach using chemotherapy, radiation, and surgery lived longer without progression of their disease than patients treated with just chemotherapy and radiation. However, it remains unclear whether three-pronged treatment extends patients’ overall survival compared to the two-pronged approach. 30.  Heart Risks of Doxorubicin Higher Than Previously Reported 7 (Posted: 05/28/2003) - A study in the June 1, 2003, issue of the journal Cancer suggests that the drug doxorubicin (Adriamycin®), widely used in cancer chemotherapy, causes congestive heart failure more frequently and at lower doses than has been reported in the past. < Previous 8  3 9 4 10 5 8 6 7 11 8 12   Next > 11

Table of Links

1	http://www.cancer.gov/cancertopics/types/lung
2	http://www.cancer.gov/clinicaltrials/search
3	http://www.cancer.gov/newscenter/pressreleases/IressaMutation
4	http://www.cancer.gov/clinicaltrials/results/surgery-and-nsclc0603
5	http://www.cancer.gov/clinicaltrials/results/pemetrexed-and-lung-cancer0603
6	http://www.cancer.gov/clinicaltrials/results/three-pronged-approach0603
7	http://www.cancer.gov/clinicaltrials/results/congestive-heart-failure0503
8	http://www.cancer.gov/clinicaltrials/results/lung?keyword=lung+any&page=5
9	http://www.cancer.gov/clinicaltrials/results/lung?keyword=lung+any&page=3
10	http://www.cancer.gov/clinicaltrials/results/lung?keyword=lung+any&page=4
11	http://www.cancer.gov/clinicaltrials/results/lung?keyword=lung+any&page=7
12	http://www.cancer.gov/clinicaltrials/results/lung?keyword=lung+any&page=8